Skip to main content
Premium Trial:

Request an Annual Quote

Interpace Biosciences Q2 Revenues Decline 14 Percent

NEW YORK – Interpace Biosciences reported before the open of the market Tuesday that its second quarter revenues fell 14 percent year over year.

For the three months ended June 30, the Parsippany, New Jersey-based cancer diagnostics firm reported revenues of $5.4 million, down from $6.3 million in the year-ago quarter and missing the consensus Wall Street estimate of $5.9 million.

"I am proud during [the COVID-19 pandemic] that we managed our costs effectively, continued to service customers and physicians, improved reimbursements, produced solid clinical results and grew our pharma services backlog while protecting our employees and seeking to operate as effectively and efficiently as possible," Jack Stover, president and CEO of Interpace, said in a statement.

The firm noted that its Q2 pharma services entered into about $9 million of new agreements, which it believes has established the opportunity for future revenues. The firm had previously acquired Cancer Genetics' biopharma service business in Q3 2019 as part of its plans to expand into the biopharma sector.

Interpace had delayed filing of its second quarter 10-Q due to an investigation regarding an employee claim of inappropriate billing practices, which was originally announced in August. However, Stover said in a statement that the external audit committee investigation found all claims to be unsubstantiated.

The firm posted a net loss of $5.5 million, or $1.36 per share, for the quarter, compared to a net loss of $5.2 million, or $1.37 per share, in the year-ago period. On an adjusted basis, the firm's net loss for the quarter was $1.34, beating the consensus Wall Street estimate for a loss of $1.48 per share.

Interpace's R&D spending fell 15 percent year over year to $550,000, from $647,000 in Q2 2019, while its sales, marketing, general, and administrative costs remained the same at $5.7 million.

The company finished the quarter with $15.1 million in cash and cash equivalents.

Interpace is projecting third quarter revenue of between $7.5 million and $7.8 million.

In Wednesday morning trading on the Nasdaq, shares of Interpace were down about 6 percent at $3.73.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more